World’s First! Verified the Efficacy and Safety of Immune Checkpoint Inhibitor “Opdivo” in Advanced Hepatocellular Carcinoma Patients with Poor Liver Function -- Kindai University
Verified the efficacy of immune checkpoint inhibitor (Opdivo) in patients with advanced hepatocellular carcinoma (aHCC) and mild to moderate impairment of liver function (Child-Pugh B class). Kindai University School of Medicine led the international collaborative research for aHCC patients with liver dysfunction for which no treatment options were available before.
